We are live on ! Find out more
NMC

NEA Management Company Portfolio holdings

AUM $1.76B
1-Year Est. Return 223.33%
This Fund
S&P 500
This Quarter Est. Return
+12.06%
1 Year Est. Return
+223.33%
3 Year Est. Return
+769.45%
5 Year Est. Return
+668.45%
10 Year Est. Return
+14,843.34%
AUM
$2.32B
AUM Growth
+$183M
Cap. Flow
+$191M
Cap. Flow %
8.24%
Top 10 Hldgs %
64.77%
Holding
46
New
3
Increased
2
Reduced
1
Closed
2

Top Buys

Rank Stock Value
1
ALLK
Allakos
ALLK
+$93.1M
2
LQDA icon
Liquidia Corp
LQDA
+$40.8M
3
BE icon
Bloom Energy
BE
+$37.3M
4
ADAP
Adaptimmune Therapeutics
ADAP
+$26.2M
5
AVEO
AVEO Pharmaceuticals, Inc.
AVEO
+$2.35M

Top Sells

Rank Stock Value
1
MDB icon
MongoDB
MDB
+$7.45M
2
TNTR
Tintri, Inc. Common Stock
TNTR
+$1.3M
3
RGLS
Regulus Therapeutics
RGLS
+$264

Sector Composition

Rank Sector Weight
1 Healthcare 94.39%
2 Industrials 1.96%
3 Technology 0.59%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TSRO
1
DELISTED
TESARO, Inc.
TSRO
$407M 17.54%
10,420,555
– –
ADAP
2
DELISTED
Adaptimmune Therapeutics
ADAP
$215M 9.26%
15,832,611
+2,500,000
+19% +$26.2M
SENS icon
3
Senseonics Holdings Inc
SENS
$258M
$147M 6.36%
1,544,413
– –
RYTM icon
4
Rhythm Pharmaceuticals
RYTM
$7.36B
$143M 6.18%
4,912,306
– –
CBIO
5
Crescent Biopharma
CBIO
$586M
$131M 5.65%
90,890
– –
ALLK
6
DELISTED
Allakos
ALLK
$102M 4.4%
+2,268,188
New +$93.1M
RARX
7
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$99.4M 4.29%
5,493,636
– –
CRSP icon
8
CRISPR Therapeutics
CRSP
$4.66B
$92.7M 4%
2,090,678
– –
OBSV
9
DELISTED
ObsEva SA Ordinary Shares
OBSV
$82.7M 3.57%
4,586,563
– –
MRSN
10
DELISTED
Mersana Therapeutics
MRSN
$81.4M 3.51%
325,771
– –
EPZM
11
DELISTED
Epizyme, Inc
EPZM
$68.5M 2.96%
6,460,851
– –
LQDA icon
12
Liquidia Corp
LQDA
$7.6B
$68.2M 2.94%
+2,486,062
New +$40.8M
ARDX icon
13
Ardelyx
ARDX
$1.25B
$66.7M 2.88%
15,335,047
– –
AVEO
14
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$61.9M 2.67%
1,869,804
+91,432
+5% +$2.35M
SYBX
15
DELISTED
Synlogic
SYBX
$60.1M 2.59%
281,961
– –
BE icon
16
Bloom Energy
BE
$46.3B
$45.4M 1.96%
+1,333,333
New +$37.3M
DERM
17
DELISTED
Dermira, Inc.
DERM
$38.2M 1.65%
3,506,649
– –
SURF
18
DELISTED
Surface Oncology, Inc. Common Stock
SURF
$36.3M 1.57%
3,315,149
– –
AUPH icon
19
Aurinia Pharmaceuticals
AUPH
$1.92B
$31.9M 1.38%
4,808,483
– –
CSBR icon
20
Champions Oncology
CSBR
$75.2M
$27.3M 1.18%
1,562,500
– –
RGLS
21
DELISTED
Regulus Therapeutics
RGLS
$26M 1.12%
91,575
-8
-0% -$264
LXRX icon
22
Lexicon Pharmaceuticals
LXRX
$1.03B
$25.4M 1.1%
2,382,286
– –
LITS
23
Lite Strategy Inc
LITS
$32.8M
$24.7M 1.06%
286,029
– –
CMTA
24
DELISTED
Clementia Pharmaceuticals Inc.
CMTA
$23.9M 1.03%
2,141,697
– –
AFMD
25
DELISTED
Affimed
AFMD
$22.4M 0.96%
513,889
– –
1
2

Similar funds

NM
NWI Management New York $1.76B AUM 45.08% 1-Year Est. Return
SLF
Sun Life Financial Toronto, Ontario, Canada $1.76B AUM 19.57% 1-Year Est. Return
CCIA
Campbell & Co Investment Adviser Baltimore, Maryland $1.76B AUM 13.06% 1-Year Est. Return
SW
Simplicity Wealth Summit, New Jersey $1.76B AUM 20.49% 1-Year Est. Return
CGH
Contrarius Group Holdings Hamilton, Bermuda $1.77B AUM 83.15% 1-Year Est. Return
PWP
Principle Wealth Partners Madison, Connecticut $1.75B AUM 21.63% 1-Year Est. Return
CIP
CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return
KOCAA
Knights of Columbus Asset Advisors New Haven, Connecticut $1.77B AUM 31.28% 1-Year Est. Return

NEA Management Company's Q3 2018 Portfolio in Review

As of Q3 2018, NEA Management Company held 46 positions worth $2.32B, up 8.6% from $2.13B the previous quarter. Its ten largest holdings account for 65% of the portfolio.

NEA Management Company deployed $191M of net new capital in Q3 2018, opening 3 new positions and adding to 2 existing holdings. Its largest new stake was Allakos: 2,268,188 shares worth $102M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 95% a quarter earlier, followed by Industrials and Technology.

On the sell side, the largest reduction was Regulus Therapeutics, an estimated $264 trimmed.

  • NEA Management Company's largest Q3 2018 buy was Allakos: 2,268,188 shares worth $102M.
  • NEA Management Company added most to Adaptimmune Therapeutics in Q3 2018, an estimated $26.2M increase.
  • NEA Management Company's biggest Q3 2018 reduction was Regulus Therapeutics, cutting an estimated $264.
  • NEA Management Company fully exited MongoDB in Q3 2018, selling an estimated $7.45M.
  • NEA Management Company's ten largest holdings make up 65% of its $2.32B portfolio in Q3 2018.
  • NEA Management Company opened 3 new positions and closed 2 in Q3 2018.
  • NEA Management Company's portfolio value rose 8.6% quarter-over-quarter to $2.32B.

Based on NEA Management Company's 13F filing for Q3 2018, filed 13 Nov 2018.